ConductScience.org, home

Paper36959353

Optimizing human α-galactosidase for treatment of Fabry disease.

Hallows WC and 18 others. Sci Rep, 2023. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Optimizing human α-galactosidase for treatment of Fabry disease. Papers, record 36959353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36959353

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimizing human α-galactosidase for treatment of Fabry disease.
PubMed
Journal
Sci Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
1.61
iCite
Revised in PubMed
2023-04-18
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hallows WCWilliam C
2Skvorak KKristen
3Agard NNick
4Kruse NNikki
5Zhang XXiyun
6Zhu YYu
7Botham RCRachel C
8Chng CChinping
9Shukla CCharu
10Lao JJessica
11Miller MMathew
12Sero AAntoinette
13Viduya JJudy
14Ismaili MHAMoulay Hicham Alaoui
15McCluskie KKerryn
16Schiffmann RRaphael
17Silverman APAdam P
18Shen JSJin-Song
19Huisman GWGjalt W

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Fabry DiseaseMajor topic
Humans
Mice
Animals
alpha-Galactosidase
Kidney
Disease Models, Animal
Fibroblasts

Source PubMed

Download CSV of topics

References65

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131836927Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.Eur J Clin Pharmacol2020https://conductscience.org/library/papers/31836927PubMed
231951773In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance.Hum Vaccin Immunother2020https://conductscience.org/library/papers/31951773PubMed
311758673Natural history of Fabry disease in affected males and obligate carrier females.J Inherit Metab Dis2001https://conductscience.org/library/papers/11758673PubMed
427555236Fabry Disease: A Disorder of Childhood Onset.Pediatr Neurol2016https://conductscience.org/library/papers/27555236PubMed
520345279New strategies for enzyme replacement therapy for lysosomal storage diseases.Rejuvenation Res2010https://conductscience.org/library/papers/20345279PubMed
622195554The molecular basis of pharmacological chaperoning in human α-galactosidase.Chem Biol2011https://conductscience.org/library/papers/22195554PubMed
726310963Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice.J Inherit Metab Dis2016https://conductscience.org/library/papers/26310963PubMed
827523577Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.Bioanalysis2016https://conductscience.org/library/papers/27523577PubMed
929880732A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse.Pharmaceutics2018https://conductscience.org/library/papers/29880732PubMed
1030198337MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena.Expert Rev Proteomics2018https://conductscience.org/library/papers/30198337PubMed
112357375Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction.Biotechniques1990https://conductscience.org/library/papers/2357375PubMed
1230834538Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.J Inherit Metab Dis2019https://conductscience.org/library/papers/30834538PubMed
1317224688Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.Genet Med2007https://conductscience.org/library/papers/17224688PubMed
1419853240Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.Am J Hum Genet2009https://conductscience.org/library/papers/19853240PubMed
1532274449Current and Investigational Therapeutics for Fabry Disease.Kidney Int Rep2020https://conductscience.org/library/papers/32274449PubMed
1632738442Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the α-galactosidase A active site, dimer interface, and glycosylation region.Protein Expr Purif2020https://conductscience.org/library/papers/32738442PubMed
1729698600Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease.Bioconjug Chem2018https://conductscience.org/library/papers/29698600PubMed
1826597321Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.Mol Genet Metab2016https://conductscience.org/library/papers/26597321PubMed
1927834756Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.J Med Genet2017https://conductscience.org/library/papers/27834756PubMed
2019846852X-linked thrombophilia with a mutant factor IX (factor IX Padua).N Engl J Med2009https://conductscience.org/library/papers/19846852PubMed

See all 65 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42344794Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy.Front Pharmacol2026https://conductscience.org/library/papers/42344794PubMed
42292401Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment.Front Immunol2026https://conductscience.org/library/papers/42292401PubMed
42211051Pathophysiological mechanisms of organ injury in Fabry disease: Update via multi-omics.Genes Dis2026https://conductscience.org/library/papers/42211051PubMed
41712507Catalyzing Carbohydrate Cleavage: Glycosidases and Their Mechanisms.Chem Rev2026https://conductscience.org/library/papers/41712507PubMed
41171875One SQ HEDGES DNA vector only dose produces durable hGLA or anti-SARS-CoV-2 mAb therapeutic serum protein levels.PLoS One2025https://conductscience.org/library/papers/41171875PubMed
40762941Galacto-oligosaccharides enrich galactosidase-encoded rather than all Lachnospiraceae bacteria to redress abnormal gut microbiota and lipid metabolism in pregnancy.Sci China Life Sci2026https://conductscience.org/library/papers/40762941PubMed
40420145Current status of the immunogenicity of enzyme replacement therapy in fabry disease.Orphanet J Rare Dis2025https://conductscience.org/library/papers/40420145PubMed
40149554Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy.Biomedicines2025https://conductscience.org/library/papers/40149554PubMed
39687734Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease.Mol Ther Methods Clin Dev2024https://conductscience.org/library/papers/39687734PubMed
39468034Dirichlet latent modelling enables effective learning and sampling of the functional protein design space.Nat Commun2024https://conductscience.org/library/papers/39468034PubMed
38667321Flow Cytometry-Based Assay to Detect Alpha Galactosidase Enzymatic Activity at the Cellular Level.Cells2024https://conductscience.org/library/papers/38667321PubMed
38371570Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage.Indian J Dermatol2023https://conductscience.org/library/papers/38371570PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36959353

GET https://conductscience.org/api/papers/v1/36959353/references?page=2